BiotechTube

humanised monoclonal antibody, veltuzumab + humanised monoclonal antibody epratuzumab + humanised monoclonal antibodies veltuzumab and epratuzumab

Phase 1/2UNKNOWN
0 views this week 0 watching💤 Quiet
Interest: 28/100
28
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Recurrent or Refractory B Cell Acute Lymphoblastic Leukaemia

Conditions

Recurrent or Refractory B Cell Acute Lymphoblastic Leukaemia

Trial Timeline

Jan 1, 2010 → Aug 1, 2014

NCT ID
NCT01279707

About humanised monoclonal antibody, veltuzumab + humanised monoclonal antibody epratuzumab + humanised monoclonal antibodies veltuzumab and epratuzumab

humanised monoclonal antibody, veltuzumab + humanised monoclonal antibody epratuzumab + humanised monoclonal antibodies veltuzumab and epratuzumab is a phase 1/2 stage product being developed by Gilead Sciences for Recurrent or Refractory B Cell Acute Lymphoblastic Leukaemia. The current trial status is unknown. This product is registered under clinical trial identifier NCT01279707. Target conditions include Recurrent or Refractory B Cell Acute Lymphoblastic Leukaemia.

What happened to similar drugs?

4 of 20 similar drugs in Recurrent or Refractory B Cell Acute Lymphoblastic Leukaemia were approved

Approved (4) Terminated (0) Active (16)
🔄Rilonacept + PlaceboKiniksa PharmaceuticalsPhase 3
✅Zopapogene imadenovec (Zopa)PrecigenApproved
🔄E7777 9 mcg/kgEisaiPhase 3
🔄Nivolumab + Gemcitabine + Cisplatin + Carboplatin + Paclitaxel + PemetrexedOno PharmaceuticalPhase 3
🔄Chemotherapy + Pembrolizumab + RamucirumabEli LillyPhase 3
🔄Abiraterone Acetate + Bicalutamide + Leuprolide + Prednisone + RelugolixSumitomo PharmaPhase 3
🔄SHR-A1811 Injection + SHR-A1811 Injection ； Pertuzumab Injection + Trastuzumab Injection；Pertuzumab Injection ； Docetaxel InjectionJiangsu Hengrui MedicinePhase 3

Hype Score Breakdown

Clinical
9
Activity
4
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT01279707Phase 1/2UNKNOWN

Competing Products

20 competing products in Recurrent or Refractory B Cell Acute Lymphoblastic Leukaemia

See all competitors
ProductCompanyStageHype Score
Doxorubicin Hydrochloride Liposome InjectionDr. Reddy's LaboratoriesPhase 1
26
KPL-914Kiniksa PharmaceuticalsPhase 2
29
KPL-387Kiniksa PharmaceuticalsPhase 2
36
Rilonacept + PlaceboKiniksa PharmaceuticalsPhase 3
34
Enzastaurin (LY317615) + CarboplatinEli LillyPhase 1
29
Zopapogene imadenovec (Zopa)PrecigenApproved
44
PRGN-2012 - Phase I; Dose Level 1 + PRGN-2012 - Phase I; Dose Level 2 + PRGN-2012 - Phase II; Dose Level 2PrecigenPhase 1/2
30
[203Pb]VMT01 + [212Pb]VMT01 + NivolumabPerspective TherapeuticsPhase 1/2
33
Ramucirumab + PembrolizumabEli LillyPhase 2
39
Gemcitabine and UFTE chemotherapyYuhanPhase 2
35
Raludotatug Deruxtecan + Carboplatin + Paclitaxel + Bevacizumab + Rescue Medication + PembrolizumabDaiichi SankyoPhase 1/2
39
Ifinatamab deruxtecanDaiichi SankyoPhase 2
42
Trastuzumab DeruxtecanDaiichi SankyoPhase 1
36
PLX3397Daiichi SankyoPhase 2
27
erlotinib + etoposideAstellas PharmaPhase 2
27
Drug Combination TherapySun PharmaceuticalPhase 2
42
Niraparib + AnlotinibSun PharmaceuticalPhase 2
35
Eribulin MesylateEisaiPre-clinical
26
Lenvatinib + EverolimusEisaiPhase 1/2
32
E7090EisaiPhase 2
42